9 active
/
49 total (since 2015)
1
Phase 1 Active
11 total
6
Phase 2 Active
23 total
4
Phase 3 Active
14 total
0
Phase 4 Active
4 total
Top Sponsors (Industry)
Sorted by active Active Done Failed
Takeda 3 5 2
Centessa Pharmaceuticals (UK) Limited 2 0 0
Jazz Pharmaceuticals 1 7 0
Alkermes, Inc. 1 2 0
NLS Pharmaceutics 1 2 0
Axsome Therapeutics, Inc. 0 4 0
Merck 0 2 1
NCT06767683 RECRUITING
A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia
Alkermes, Inc. n=256
NCT07363720 NOT YET RECRUITING
A Trial of TAK-861 for the Treatment of Narcolepsy With Cataplexy
Takeda n=88
NCT05816382 RECRUITING
A Study of TAK-861 for the Treatment of Selected Central Hypersomnia Conditions
Takeda n=500
NCT05914194 NOT YET RECRUITING
A Eight-Week Study of NLS-2 (Mazindol Extended Release) in Participants With Narcolepsy Type 1
NLS Pharmaceutics n=48
NCT05113745 COMPLETED
A Study to Assess the Long-term Efficacy and Safety of AXS-12 (Reboxetine) in Subjects With Narcolepsy (ENCORE)
Axsome Therapeutics, Inc. n=68
NCT02611687 COMPLETED
Efficacy and Safety of Pitolisant in Pediatric Narcoleptic Patients With or Without Cataplexy, Double-blind Study Followed by a Prolonged Open-label Period
Bioprojet n=110
NCT05059223 COMPLETED
A Study to Assess the Efficacy and Safety of AXS-12 (Reboxetine) in Patients With Narcolepsy
Axsome Therapeutics, Inc. n=90
NCT02720744 COMPLETED
Once-Nightly Sodium Oxybate for Treatment of Excessive Daytime Sleepiness and Cataplexy in Narcolepsy
Avadel n=212
NCT03030599 COMPLETED
A Study of the Efficacy and Safety of JZP-258 in Subjects With Narcolepsy With Cataplexy
Jazz Pharmaceuticals n=201
NCT02348593 COMPLETED
"Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in Narcolepsy"
Jazz Pharmaceuticals n=239
NCT02348632 COMPLETED
"A Long-Term Safety Study of JZP-110 in the Treatment of Excessive Sleepiness in Subjects With Narcolepsy or OSA"
Jazz Pharmaceuticals n=645
Data: ClinicalTrials.gov